These findings revealed that circCRKL inhibited the progression of PCa through upregulating KLF5 expression by sponging miR-141, elucidating a novel regulatory pathway in PCa cells. Our research suggested an underlying circRNA-targeted therapy for PCa.
circCRKL suppresses the progression of prostate cancer cells by regulating the miR-141/KLF5 axis.